India’s Meril Transforms Heart Care with Myval Octapro THV
Newzdaddy Health And Fitness Updates
Synopsis of the Article
- Meril Life Sciences introduced the Myval Octapro Transcatheter Heart Valve (THV) at GISE 2024 and PCR London Valves 2024.
- The Myval Octapro THV boasts enhanced operator control, precise deployment, and a versatile size matrix.
- Myval Octapro THV sets new benchmarks in transcatheter aortic valve replacement (TAVR) procedures.
- Dr. Ashok Seth praised the innovation, citing its effectiveness, safety, and advanced features.
- Comparative studies, including the LANDMARK trial and COMPARE-TAVI trial, showed the Myval THV series’ superiority in several clinical aspects.
- Myval THV demonstrated reduced permanent pacemaker implantation rates and better hemodynamic performance.
- The COMPARE-TAVI trial confirmed Myval THV’s non-inferiority to the Sapien THV series and highlighted reduced patient-prosthesis mismatch (PPM).
- The Myval Octapro THV emphasizes Meril’s commitment to improving patient outcomes through innovation.
Meril Life Sciences: Advancing Cardiac Care with Myval Octapro THV
On November 27, 2024, Gujarat-based Meril Life Sciences took the global stage by storm, introducing its latest innovation, the Myval Octapro Transcatheter Heart Valve (THV). This cutting-edge solution was showcased at two prestigious scientific events—GISE 2024 (Italy) and PCR London Valves 2024 (UK). Both events are renowned for gathering the world’s leading experts in interventional cardiology and structural heart solutions.
Myval Octapro THV: Redefining TAVR Procedures
The Myval Octapro THV represents a leap forward in transcatheter aortic valve replacement (TAVR) technology. Designed with low frame foreshortening, this device allows for precise deployment, giving surgeons greater control and confidence during procedures. Additionally, its wide range of sizes—including conventional, intermediate, and extra-large—caters to diverse patient anatomies, ensuring personalized and effective treatment.
Expert Endorsements: A Testament to Innovation
Dr. Ashok Seth, Chairman of Fortis Escorts Heart Institute, hailed the Myval Octapro THV as a groundbreaking development. He highlighted its minimal foreshortening and advanced commissural alignment, which contribute to accurate implantation. “The inclusion of intermediate and extra-large sizes makes this device a game-changer, as approximately 50% of Myval THV implants are intermediate-sized,” he noted.
Global Acclaim at PCR London Valves 2024
At PCR London Valves 2024, Meril presented findings from the LANDMARK trial and other comparative studies, published in the EuroIntervention Journal. These studies demonstrated the Myval THV series’ non-inferiority to competitors like Sapien and Evolut valves in key metrics such as safety, effectiveness, and hemodynamic performance.
The Myval THV series showed:
- Reduced rates of permanent pacemaker implantation (15% vs. 17.3% with Sapien).
- Superior hemodynamic outcomes with minimal valve regurgitation.
- Comparable or better performance in critical clinical measures against leading alternatives.
Must Read:
Shree Vidhyaguru Foundation Celebrates a Decade of Free Healthcare, Promising a Century of Service
COMPARE-TAVI Trial: A First-of-its-Kind Study
Another highlight of the event was the COMPARE-TAVI trial, presented by Prof. Henrik Nissen. This randomized controlled trial directly compared the Myval THV series with the Sapien THV series in real-world scenarios. The results were groundbreaking:
- Myval THV met the non-inferiority criteria for composite safety and effectiveness outcomes at one year.
- It showed a significantly lower incidence of patient-prosthesis mismatch (PPM) (17.5% vs. 28.6%), a crucial factor in long-term patient outcomes.
A Commitment to Innovation and Patient Care
Meril’s Sanjeev Bhatt, Senior VP of Corporate Strategy, expressed pride in the positive global reception of the Myval Octapro THV. “Our collaboration with clinicians worldwide reinforces our mission to advance TAVR technology and improve lives through innovation,” he said.
A New Era in Structural Heart Care
The Myval Octapro THV underscores Meril’s dedication to excellence in cardiovascular care. With reduced procedural risks, tailored solutions for diverse anatomies, and superior performance metrics, this innovation sets a new standard in structural heart interventions.
The Way Forward for Meril
As the Myval Octapro THV gains global recognition, Meril remains steadfast in its mission to transform cardiac care. With continued collaborations and groundbreaking research, the company is poised to lead the next wave of innovation in TAVR and structural heart solutions.
Must Read:
Meril’s “Treatment Zaroori Hai” Campaign: A Personalized Approach to Healthcare